Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Törn, Carina ^a   Liu, Xiang ^b   Hagopian, William ^c   Lernmark, Åke ^a   Simell, Olli ^d   Rewers, Marian ^e   Ziegler, Anette G ^f   Schatz, Desmond ^g   Akolkar, Beena ^h   Onengut Gumuscu, Suna ⁱ   Chen, Wei Min ⁱ   Toppari, Jorma ^d,j   Mykkänen, Juha ^d,j   Ilonen, Jorma ^j   Rich, Stephen S ⁱ   She, Jin Xiong ^k   Sharma, Ashok ^k   Steck, Andrea ^e   Krischer, Jeffrey ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF COLORADO DENVER   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j UNIVERSITY OF TURKU   (Finland)

^k MEDICAL COLLEGE OF GEORGIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3;

CLINICAL TRIAL; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTICENTER STUDY; NEWBORN; PANCREAS ISLET BETA CELL; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

AUTOANTIBODIES; CHILD, PRESCHOOL; COMPLEMENT C3; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INSULIN-SECRETING CELLS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84975091581     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27887     Document Type: Article

References (42)

1. Rowe, P. et al. Increased complement activation in human type 1 diabetes pancreata. Diabetes Care 36, 3815-3817 (2013).
2. Zhang, Q. et al. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes. J Exp Med. 210, 191-203 (2013).
3. Hoffman, W. H., Cudrici, C. D., Zafranskaia, E. & Rus, H. Complement activation in diabetic ketoacidosis brains. Exp Mol Pathol. 80, 283-288 (2006).
4. Kallionpaa, H. et al. Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 63, 2402-2414 (2014).
5. Idahl, L. A., Sehlin, J., Taljedal, I. B. & Thornell, L. E. Cytotoxic activation of complement by mouse pancreatic islet cells. Diabetes 29, 636-642 (1980).
6. Alper, C. A., Awdeh, Z. L. & Yunis, E. J. Complotypes and extended haplotypes in laboratory medicine. Complement Inflamm. 6, 8-18 (1989).
7. McCluskey, J. et al. HLA and complement allotypes in Type 1 (insulin-dependent) diabetes. Diabetologia 24, 162-165 (1983).
8. Rich, S. S., Weitkamp, L. R. & Barbosa, J. Genetic heterogeneity of insulin-dependent (type I) diabetes mellitus: evidence from a study of extended haplotypes. Am J Hum Genet. 36, 1015-1023 (1984).
9. Zavattari, P. et al. Conditional linkage disequilibrium analysis of a complex disease superlocus, IDDM1 in the HLA region, reveals the presence of independent modifying gene effects influencing the type 1 diabetes risk encoded by the major HLA-DQB1,-DRB1 disease loci. Hum Mol Genet. 10, 881-889 (2001).
10. Nejentsev, S. et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450, 887-892 (2007).
11. Noble, J. A. et al. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 59, 2972-2979 (2010).
12. Chen, M., Daha, M. R. & Kallenberg, C. G. The complement system in systemic autoimmune disease. J Autoimmun. 34, J276-286 (2010).
13. Holers, V. M. Complement and its receptors: new insights into human disease. Ann Rev Immunol. 32, 433-459 (2014).
14. Sosenko, J. M. et al. A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 31, 528-533 (2008).
15. Gepts, W. & Lecompte, P. M. The pancreatic islets in diabetes. Am J Med. 70, 105-115 (1981).
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 33 Suppl 1, S62-69 (2010).
17. Lambert, A. P. et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: A population-based study in the United Kingdom. J Clin Endocrinol Metab. 89, 4037-4043 (2004).
18. Barrett, J. C. et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 41, 703-707 (2009).
19. Cooper, J. D. et al. Confirmation of novel type 1 diabetes risk loci in families. Diabetologia 55, 996-1000 (2012).
20. Seddon, J. M. Complement factor 3 variation is associated with AMD risk. Retina Today 37-39 (2008).
21. Arvilommi, H. Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature 251, 740-741 (1974).
22. Yates, J. R. et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 357, 553-561 (2007).
23. Zhang, M. X. et al. Association between a functional genetic polymorphism (rs2230199) and age-related macular degeneration risk: A meta-analysis. Genet Mol Res. 14, 12567-12576 (2015).
24. Hess, K. et al. A novel mechanism for hypofibrinolysis in diabetes: The role of complement C3. Diabetologia 55, 1103-1113 (2012).
25. Zhou, Y. et al. Multiple lupus-associated ITGAM variants alter Mac-1 functions on neutrophils. Arthritis Rheum. 65, 2907-2916 (2013).
26. Douglas, K. B. et al. Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing. Genes Immun. 10, 457-469 (2009).
27. Solovjov, D. A., Pluskota, E. & Plow, E. F. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem. 280, 1336-1345 (2005).
28. Fagerholm, S. C., MacPherson, M., James, M. J., Sevier-Guy, C. & Lau, C. S. The CD11b-integrin (ITGAM) and systemic lupus erythematosus. Lupus. 22, 657-663 (2013).
29. Gauffre, A. et al. Nuclear localization of the Epstein-Barr virus/C3d receptor (CR2) in the human Burkitt B lymphoma cell, Raji. Mol Immunol. 29, 1113-1120 (1992).
30. Cherukuri, A., Cheng, P. C. & Pierce, S. K. The role of the CD19/CD21 complex in B cell processing and presentation of complementtagged antigens. J Immunol. 167, 163-172 (2001).
31. Sjoberg, A. P., Trouw, L. A. & Blom, A. M. Complement activation and inhibition: A delicate balance. Trends Immunol. 30, 83-90 (2009).
32. The TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 8, 286-298 (2007).
33. Hagopian, W. A. et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 12, 733-743 (2011).
34. Torn, C., Mueller, P. W., Schlosser, M., Bonifacio, E. & Bingley, P. J. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51, 846-852 (2008).
35. Babaya, N. et al. Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays. Diabetes Metab Res Rev. 25, 665-670 (2009).
36. Bonifacio, E. et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. J Clin Endocrinol Metab. 95, 3360-3367 (2010).
37. Schlosser, M. et al. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 53, 2611-2620 (2010).
38. Dantonio, P. et al. Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots. J Diabetes Sci Technol. 4, 929-941 (2010).
39. Torn, C. et al. Role of Type 1 diabetes associated SNPs on risk of autoantibody positivity in the TEDDY Study. Diabetes 64, 1818-1829 (2015).
40. Wei, L. J., Lin, D. Y. & Weissfeld, L. Regression analysis of multivariate incomplete failure time data by modeling marginal distribution. J Am Stat Assoc. 84, 1065-1073 (1989).
41. Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 81, 559-575 (2007).
42. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 38, 904-909 (2006).